Pilot Project to determine acid-base effects of Sodiumglucose Cotransporter-2 (SGLT2) Inhibitors

This study explores how diabetes affects the body’s mineral balance—something that hasn’t been well understood. Researchers are especially focused on a type of diabetes drug (SGLT2 inhibitors) that helps with blood sugar and heart health but may cause unusual side effects.

Study Status


Enrollment Period


Eligibility Criteria


Accepts Healthy Volunteers
No

Contact Information


Tulane Center for Clinical Research
504-988-0200

Select a tab above for more information.

 

Who Qualifies for this Study?

PI Initiated Kathleen Hering-Smith, PhD., Vivian Fonseca, MD, Lee Hamm, MD

Protocol: 985661 

Diabetes is well known to cause proteinuria (protein in urine), chronic kidney disease, and end-stage renal disease. These have been, and continue to be, appropriately well-studied. The purpose of this research study is to study the variety of electrolyte disorders (Electrolyte disorders result in an imbalance of minerals in the body. For the body to function properly, certain minerals need to be maintained in an even balance. Otherwise, vital body systems, such as the muscles and brain, can be negatively affected.) which have not been well studied, particularly with currently available techniques. 

Our long-term goal is to understand these diabetic electrolyte disorders using such up-to-date techniques to understand electrolyte disorders. The current focus will be on sodium glucose cotransporter 2 inhibitors (SGLT2i) which have been found to cause an unusual form of diabetic ketoacidosis (high levels of blood acids called ketones) which appears much different than that long known in type 1 diabetes (T1DM). SGLT2i were introduced into clinical practice for type 2 diabetes (T2DM) in 2013. They increase urinary glucose excretion and thereby improve glycemic control. They have many favorable attributes including weight loss. 

Most significantly, one agent (empagliflozin) has recently been shown to have impressive benefits on all cause and cardiovascular mortality and on hospitalizations for heart failure. This contrasts dramatically with almost all other agents which reduce serum glucose. Importantly, these effects also began to be seen very early (3 months) and were seemingly independent of most cardiovascular determinants (risk factors for cardiovascular disease include behavioral factors as well as such social factors as poverty, stress, and hereditary factors). There were also favorable outcomes for kidney injury as well. Thus, these impressive results from SGLT2i point toward their expanded use in patients with diabetes. 

Study Overview

While it's well known that diabetes can lead to kidney damage and protein in the urine, this study looks at a less explored issue—how diabetes affects the balance of important minerals in the body, called electrolytes. These imbalances can harm the muscles, brain, and other vital systems. The research focuses on a newer class of diabetes medications called SGLT2 inhibitors, which help control blood sugar and offer major heart and kidney benefits. However, they can also cause a rare and unusual form of diabetic ketoacidosis. The goal is to better understand how these drugs affect the body’s chemistry using the most current medical techniques.

Conditions / Diseases


Diabetes

Department / Organizations


Tulane Center for Clinical Research (TCCR)

Principal Investigator


ClinicalTrials.gov


Join a Clinical Trial Today

Help advance medicine and make a difference.

Frequently Asked Questions


We understand that deciding to join a clinical trial is a personal choice—and often one that comes with a lot of questions. Whether you're curious about how trials work, wondering about safety, or just want to know what to expect, you're in the right place.

What is a clinical trial?

Why should I consider participating?

Is it safe?

Will I be paid?

Can I leave a study at any time?

What happens if I have side effects?

Will my personal information be kept private?

Do I need health insurance to participate?

Reach Out for More Information

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.